Concerns around dosing biomarkers and scientific-method reliability continued to surface. A translational modeling study argued that receptor occupancy may not reliably predict immune activation for pembrolizumab dosing, raising questions about assumptions used to guide immunotherapy exposure. Separately, editorial scrutiny and retractions in drug-delivery materials highlight the importance of image integrity and reproducibility for platform development.